Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

In the pivotal PULSAR and PHOTON trials, it was found to be as effective with either 12- or 16-week dosing as the original 2 mg Eylea formulation, which needs to be injected every eight weeks ...

RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

The company announced that a phase III study, MUSETTE, which compared a higher dose of Ocrevus intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose ... risen 15.2% year ...

Eylea does not have any known drug interactions. However, it’s still important to talk with your doctor about all medications, supplements, and vitamins you use before starting treatment with ...

The drug binds to VEGF – the same target as $8 billion blockbuster Eylea (aflibercept) – as well as a second target Ang-2, tackling two disease pathways associated with the sight-robbing diseases.